Merck & Cie (a subsidiary of Merck KGAA) and Bayer AG struck out in their effort to get the US Supreme Court to review the “on sale” bar provision of the Patent Act, which prevents someone from seeking a patent on an invention that has been “on sale” for more than one year prior to the patent application. And Mylan Pharmaceuticals Inc. lost a bid to get the court to limit where brand-name drug makers can file infringement suits against generic manufacturers.
In Jan. 9 orders, the court denied petitions in these cases, which were closely followed by industry. The Pharmaceutical Research...





